Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2025 00:30 ET | Source: Custom Market Insights

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal...
November 01, 2023 06:00 ET | Source: Rayzebio, Inc.

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today...
August 10, 2023 15:15 ET | Source: Spherix Global Insights

What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List

Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...
December 17, 2021 18:09 ET | Source: Zai Lab Limited

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

VYVGART is the first and only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the...
November 15, 2021 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
January 06, 2021 16:01 ET | Source: Zai Lab Limited; argenx

argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each yearZai Lab granted...